Louis G. Lange Sells 20,000 Shares of Audentes Therapeutics Inc (BOLD) Stock

Audentes Therapeutics Inc (NASDAQ:BOLD) Director Louis G. Lange sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $36.00, for a total transaction of $720,000.00. Following the transaction, the director now owns 306,099 shares in the company, valued at $11,019,564. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of BOLD stock traded up $0.37 during mid-day trading on Friday, reaching $38.90. The stock had a trading volume of 281,685 shares, compared to its average volume of 457,581. The stock has a market cap of $1.66 billion, a P/E ratio of -11.44 and a beta of 1.96. Audentes Therapeutics Inc has a 12-month low of $17.95 and a 12-month high of $46.18.

Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported ($0.84) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.08. During the same period in the previous year, the firm posted ($0.82) EPS. Analysts forecast that Audentes Therapeutics Inc will post -3.8 EPS for the current year.

Several brokerages recently weighed in on BOLD. Leerink Swann reaffirmed an “outperform” rating and set a $48.00 price target (up from $37.00) on shares of Audentes Therapeutics in a report on Wednesday. ValuEngine raised Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Monday, April 1st. Piper Jaffray Companies increased their price target on Audentes Therapeutics from $45.00 to $55.00 and gave the stock a “positive” rating in a report on Monday, April 8th. Zacks Investment Research raised Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $39.00 price target for the company in a report on Tuesday, March 5th. Finally, HC Wainwright reissued a “buy” rating and issued a $44.00 target price (up previously from $33.00) on shares of Audentes Therapeutics in a report on Monday, March 18th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $38.76.

A number of institutional investors have recently bought and sold shares of the stock. Partner Fund Management L.P. increased its position in Audentes Therapeutics by 94.4% during the 4th quarter. Partner Fund Management L.P. now owns 3,021,259 shares of the biotechnology company’s stock worth $64,413,000 after purchasing an additional 1,467,120 shares in the last quarter. BlackRock Inc. grew its holdings in Audentes Therapeutics by 15.8% in the 4th quarter. BlackRock Inc. now owns 2,974,591 shares of the biotechnology company’s stock valued at $63,418,000 after buying an additional 406,605 shares during the period. Redmile Group LLC grew its holdings in Audentes Therapeutics by 0.7% in the 3rd quarter. Redmile Group LLC now owns 2,243,356 shares of the biotechnology company’s stock valued at $88,814,000 after buying an additional 14,700 shares during the period. Great Point Partners LLC purchased a new stake in Audentes Therapeutics in the 4th quarter valued at about $35,346,000. Finally, Vanguard Group Inc. grew its holdings in Audentes Therapeutics by 1.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,342,931 shares of the biotechnology company’s stock valued at $53,166,000 after buying an additional 24,585 shares during the period.

WARNING: This report was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/audentes-therapeutics-inc-bold-director-sells-720000-00-in-stock.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

See Also: Systematic Risk

Insider Buying and Selling by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.